个人中心 - 老虎社区

HoSei

IP属地：未知

帖子 · 27帖子 · 27
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- HoSeiHoSei
  ·2021-11-29
  The new COVID-19 variant is bad news for the rest of the markets…
  Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week<blockquote>Moderna、辉瑞和Novavax是本周必须持有的股票</blockquote>
  The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday
  Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week<blockquote>Moderna、辉瑞和Novavax是本周必须持有的股票</blockquote>
  4,102 评论
  4
  分享
  举报
- HoSeiHoSei
  ·2021-11-28
  Down for 2 days in a row is serious for a reputable bank like DBS, no wonder MAS is stepping in.
  非常抱歉，此主贴已删除
  3,548 评论
  2
  分享
  举报
- HoSeiHoSei
  ·2021-11-12
  It is still a great buy for me at $22-24
  Analysts Adjust Palantir Price Targets Post Q3 Results<blockquote>分析师在第三季度业绩公布后调整Palantir价格目标</blockquote>
  Few analysts slashed price targets onPalantir Technologies Inc(NYSE:PLTR)despite the Q3 beat. RBC Ca
  Analysts Adjust Palantir Price Targets Post Q3 Results<blockquote>分析师在第三季度业绩公布后调整Palantir价格目标</blockquote>
  2,510 评论
  点赞
  分享
  举报
- HoSeiHoSei
  ·2021-11-10
  $24 range is a Great buy
  非常抱歉，此主贴已删除
  3,030 评论
  3
  分享
  举报
- HoSeiHoSei
  ·2021-11-09
  $Palantir Technologies Inc.(PLTR)$Pay day!
  3,435 评论
  1
  分享
  举报
- HoSeiHoSei
  ·2021-11-09
  $Pinterest, Inc.(PINS)$Share share
  3,016 评论
  点赞
  分享
  举报
- HoSeiHoSei
  ·2021-11-06
  $Pinterest, Inc.(PINS)$Share
  2,662 评论
  点赞
  分享
  举报
- HoSeiHoSei
  ·2021-11-05
  $Palantir Technologies Inc.(PLTR)$Share
  2,861 评论
  1
  分享
  举报
- HoSeiHoSei
  ·2021-11-05
  $Pinterest, Inc.(PINS)$Too good to miss
  3,041 评论
  1
  分享
  举报
- HoSeiHoSei
  ·2021-11-04
  $Palantir Technologies Inc.(PLTR)$To the moon tonight
  2,573 评论
  2
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3579647754039667","uuid":"3579647754039667","gmtCreate":1616554047033,"gmtModify":1617250465419,"name":"HoSei","pinyin":"hosei","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/b65f0852010eb87e540514cf7506961d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":110,"tweetSize":27,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.01","exceedPercentage":"93.08%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.43%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":600561028,"gmtCreate":1638175738678,"gmtModify":1638175771458,"author":{"id":"3579647754039667","authorId":"3579647754039667","name":"HoSei","avatar":"https://static.tigerbbs.com/b65f0852010eb87e540514cf7506961d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579647754039667","authorIdStr":"3579647754039667"},"themes":[],"title":"","htmlText":"The new COVID-19&nbsp;variant is bad news&nbsp;for the rest of the markets…","listText":"The new COVID-19&nbsp;variant is bad news&nbsp;for the rest of the markets…","text":"The new COVID-19 variant is bad news for the rest of the markets…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600561028","repostId":"1119853738","repostType":4,"repost":{"id":"1119853738","kind":"news","pubTimestamp":1638153494,"share":"https://www.laohu8.com/m/news/1119853738?lang=zh_CN&edition=full","pubTime":"2021-11-29 10:38","market":"us","language":"en","title":"Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week<blockquote>Moderna、辉瑞和Novavax是本周必须持有的股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1119853738","media":"Motley Fool","summary":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday","content":"<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.</p><p><blockquote>上周五，新出现的奥密克戎冠状病毒变种震惊了美国股市。奥密克戎让世界感到紧张，因为其独特的突变组合可能会显着降低第一代COVID-19疫苗的有效性。</blockquote></p><p> While there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.</p><p><blockquote>虽然还没有足够的数据对奥密克戎变种的严重性得出任何明确的结论，但世界各地的政界人士很快做出反应，周末对几个非洲国家实施了旅行禁令和限制。这些快速的旅行限制非常清楚地表明，全球疫情及其对世界经济的影响远未结束。</blockquote></p><p> How should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers&nbsp;<b>Moderna</b>(NASDAQ:MRNA),<b>Pfizer</b>(NYSE:PFE), and&nbsp;<b>Novavax</b>(NASDAQ:NVAX)&nbsp;all&nbsp;vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.</p><p><blockquote>投资者应该如何保护他们的投资组合免受全球供应链、国际旅行和公共卫生的最新威胁？答案似乎很简单：疫苗库存。黑色星期五，顶级COVID-19疫苗开发商的股票<b>现代</b>（纳斯达克：MRNA），<b>辉瑞</b>（纽约证券交易所代码：PFE），以及<b>Novavax</b>（纳斯达克：NVAX）全部走高。这就是为什么这三只生物制药股寻求在下周及以后继续北上。</blockquote></p><p> The pandemic's latest twist makes these three stocks screaming buys</p><p><blockquote>疫情的最新转折让这三只股票尖叫买入</blockquote></p><p> Moderna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.</p><p><blockquote>由于对奥密克戎变种的快速反应，Moderna、辉瑞和Novavax的股价在周五假期缩短的交易时段均大幅上涨。具体来说，Moderna宣布，它正在研究一种奥密克戎特异性疫苗，以及基于其目前授权的COVID-19疫苗的独特加强注射方案，这可能会针对这种新变种提供更高水平的免疫保护。</blockquote></p><p> Pfizer, for its part, said that its&nbsp;<b>BioNTech</b>-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.</p><p><blockquote>辉瑞则表示，其<b>BioNTech</b>-合作的COVID-19疫苗可以很容易地适应奥密克戎变种，并在100天内准备好使用——也就是说，如果其疫苗的原始版本无法提供足够的保护。Novavax上周五还提供了其奥密克戎疫苗战略的最新情况，该生物技术公司表示，计划在未来几周内准备好一种针对奥密克戎的疫苗进行测试和生产。</blockquote></p><p> Why are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.</p><p><blockquote>为什么这些奥密克戎定制的疫苗对其开发者来说是一个巨大的积极因素？在这一消息发布之前，Moderna和辉瑞/BioNTech的信使RNA(mRNA)疫苗似乎都处于商业保质期的后端。因此，Moderna的股价本月早些时候出现了明显的下跌趋势。对更有效的加强注射和潜在的变异特异性疫苗的突然需求应该会使Moderna的营收在2022年朝着正确的方向发展，这应该会在今年剩余时间里点燃该生物技术公司的股价。</blockquote></p><p> While Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.</p><p><blockquote>虽然辉瑞的股价最近并没有因为其口服冠状病毒药物而下跌，但这家制药巨头现在可能会受益于又一年异常强劲的COVID-19疫苗销售。反过来，辉瑞的股价可能会在2022年继续创下历史新高。</blockquote></p><p> On the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have&nbsp;dipped in the back half of 2021&nbsp;in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.</p><p><blockquote>在ledger的Novavax方面，该生物技术公司的股价目前较52周高点下跌了31%。由于制造问题、监管延误以及投资者越来越担心该公司可能只是错过了机会，这家疫苗专家的股价在2021年下半年下跌。</blockquote></p><p> What's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.</p><p><blockquote>重要的是要了解Novavax的COVID-19疫苗是基于蛋白质的，这可能会吸引许多对尖端mRNA疫苗犹豫不决的人。因此，随着Novavax在非常重要的美国市场慢慢完成监管程序，这种新变种应该会保持对Novavax替代疫苗的潜在需求偏高。</blockquote></p><p> In short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.</p><p><blockquote>简而言之，Moderna、辉瑞和Novavax都有望从其独特的疫苗开发能力中受益匪浅，这使得它们的股票本周受到了极其强劲的买入。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week<blockquote>Moderna、辉瑞和Novavax是本周必须持有的股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Pfizer, and Novavax Are Must-Own Stocks This Week<blockquote>Moderna、辉瑞和Novavax是本周必须持有的股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-29 10:38</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.</p><p><blockquote>上周五，新出现的奥密克戎冠状病毒变种震惊了美国股市。奥密克戎让世界感到紧张，因为其独特的突变组合可能会显着降低第一代COVID-19疫苗的有效性。</blockquote></p><p> While there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.</p><p><blockquote>虽然还没有足够的数据对奥密克戎变种的严重性得出任何明确的结论，但世界各地的政界人士很快做出反应，周末对几个非洲国家实施了旅行禁令和限制。这些快速的旅行限制非常清楚地表明，全球疫情及其对世界经济的影响远未结束。</blockquote></p><p> How should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers&nbsp;<b>Moderna</b>(NASDAQ:MRNA),<b>Pfizer</b>(NYSE:PFE), and&nbsp;<b>Novavax</b>(NASDAQ:NVAX)&nbsp;all&nbsp;vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.</p><p><blockquote>投资者应该如何保护他们的投资组合免受全球供应链、国际旅行和公共卫生的最新威胁？答案似乎很简单：疫苗库存。黑色星期五，顶级COVID-19疫苗开发商的股票<b>现代</b>（纳斯达克：MRNA），<b>辉瑞</b>（纽约证券交易所代码：PFE），以及<b>Novavax</b>（纳斯达克：NVAX）全部走高。这就是为什么这三只生物制药股寻求在下周及以后继续北上。</blockquote></p><p> The pandemic's latest twist makes these three stocks screaming buys</p><p><blockquote>疫情的最新转折让这三只股票尖叫买入</blockquote></p><p> Moderna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.</p><p><blockquote>由于对奥密克戎变种的快速反应，Moderna、辉瑞和Novavax的股价在周五假期缩短的交易时段均大幅上涨。具体来说，Moderna宣布，它正在研究一种奥密克戎特异性疫苗，以及基于其目前授权的COVID-19疫苗的独特加强注射方案，这可能会针对这种新变种提供更高水平的免疫保护。</blockquote></p><p> Pfizer, for its part, said that its&nbsp;<b>BioNTech</b>-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.</p><p><blockquote>辉瑞则表示，其<b>BioNTech</b>-合作的COVID-19疫苗可以很容易地适应奥密克戎变种，并在100天内准备好使用——也就是说，如果其疫苗的原始版本无法提供足够的保护。Novavax上周五还提供了其奥密克戎疫苗战略的最新情况，该生物技术公司表示，计划在未来几周内准备好一种针对奥密克戎的疫苗进行测试和生产。</blockquote></p><p> Why are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.</p><p><blockquote>为什么这些奥密克戎定制的疫苗对其开发者来说是一个巨大的积极因素？在这一消息发布之前，Moderna和辉瑞/BioNTech的信使RNA(mRNA)疫苗似乎都处于商业保质期的后端。因此，Moderna的股价本月早些时候出现了明显的下跌趋势。对更有效的加强注射和潜在的变异特异性疫苗的突然需求应该会使Moderna的营收在2022年朝着正确的方向发展，这应该会在今年剩余时间里点燃该生物技术公司的股价。</blockquote></p><p> While Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.</p><p><blockquote>虽然辉瑞的股价最近并没有因为其口服冠状病毒药物而下跌，但这家制药巨头现在可能会受益于又一年异常强劲的COVID-19疫苗销售。反过来，辉瑞的股价可能会在2022年继续创下历史新高。</blockquote></p><p> On the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have&nbsp;dipped in the back half of 2021&nbsp;in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.</p><p><blockquote>在ledger的Novavax方面，该生物技术公司的股价目前较52周高点下跌了31%。由于制造问题、监管延误以及投资者越来越担心该公司可能只是错过了机会，这家疫苗专家的股价在2021年下半年下跌。</blockquote></p><p> What's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.</p><p><blockquote>重要的是要了解Novavax的COVID-19疫苗是基于蛋白质的，这可能会吸引许多对尖端mRNA疫苗犹豫不决的人。因此，随着Novavax在非常重要的美国市场慢慢完成监管程序，这种新变种应该会保持对Novavax替代疫苗的潜在需求偏高。</blockquote></p><p> In short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.</p><p><blockquote>简而言之，Moderna、辉瑞和Novavax都有望从其独特的疫苗开发能力中受益匪浅，这使得它们的股票本周受到了极其强劲的买入。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119853738","content_text":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.\nWhile there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.\nHow should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers Moderna(NASDAQ:MRNA),Pfizer(NYSE:PFE), and Novavax(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.\nThe pandemic's latest twist makes these three stocks screaming buys\nModerna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.\nPfizer, for its part, said that its BioNTech-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.\nWhy are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.\nWhile Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.\nOn the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.\nWhat's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.\nIn short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":4102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600964410,"gmtCreate":1638056677188,"gmtModify":1638063470923,"author":{"id":"3579647754039667","authorId":"3579647754039667","name":"HoSei","avatar":"https://static.tigerbbs.com/b65f0852010eb87e540514cf7506961d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579647754039667","authorIdStr":"3579647754039667"},"themes":[],"title":"","htmlText":"Down for 2 days in a row is serious for a reputable bank like DBS, no wonder MAS is stepping in.","listText":"Down for 2 days in a row is serious for a reputable bank like DBS, no wonder MAS is stepping in.","text":"Down for 2 days in a row is serious for a reputable bank like DBS, no wonder MAS is stepping in.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600964410","repostId":"1113757092","repostType":4,"isVote":1,"tweetType":1,"viewCount":3548,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879035089,"gmtCreate":1636669247252,"gmtModify":1636669247382,"author":{"id":"3579647754039667","authorId":"3579647754039667","name":"HoSei","avatar":"https://static.tigerbbs.com/b65f0852010eb87e540514cf7506961d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579647754039667","authorIdStr":"3579647754039667"},"themes":[],"title":"","htmlText":"It is still&nbsp;a great&nbsp;buy for me at $22-24","listText":"It is still&nbsp;a great&nbsp;buy for me at $22-24","text":"It is still a great buy for me at $22-24","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879035089","repostId":"1139881214","repostType":2,"repost":{"id":"1139881214","kind":"news","pubTimestamp":1636619165,"share":"https://www.laohu8.com/m/news/1139881214?lang=zh_CN&edition=full","pubTime":"2021-11-11 16:26","market":"us","language":"en","title":"Analysts Adjust Palantir Price Targets Post Q3 Results<blockquote>分析师在第三季度业绩公布后调整Palantir价格目标</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1139881214","media":"Benzinga","summary":"Few analysts slashed price targets onPalantir Technologies Inc(NYSE:PLTR)despite the Q3 beat.\nRBC Ca","content":"<p> <ul>  <li>Few analysts slashed price targets on<b>Palantir Technologies Inc</b>(NYSE:PLTR)despite the Q3 beat.</p><p><blockquote><ul><li>很少有分析师大幅下调目标价<b>Palantir技术公司</b>（纽约证券交易所股票代码：PLTR）尽管第三季度表现良好。</li></ul></blockquote></p><p></li>  <li><b>RBC Capital</b>analyst Rishi Jaluria downgraded toUnderperform from Sector Performwith a price target of $19, down from $25, implying a 17% downside.</p><p><blockquote><li><b>加拿大皇家银行资本</b>分析师Rishi Jaluria将行业表现评级从行业表现下调至表现不佳，目标价从25美元降至19美元，意味着下跌17%。</li></blockquote></p><p></li>  <li>The analyst cites the company's \"mixed\" Q3 results with deceleration in the government business while noting that its commercial acceleration that is being fueled by SPAC investments is \"unsustainable.\"</p><p><blockquote><li>该分析师指出，该公司第三季度业绩“好坏参半”，政府业务放缓，同时指出，SPAC投资推动的商业加速是“不可持续的”。</li></blockquote></p><p></li>  <li>Jaluria adds that his confidence in Palantr's 30% growth is reduced, and he sees the stock's valuation as \"full.\"</p><p><blockquote><li>Jaluria补充说，他对Palantr 30%增长的信心降低，他认为该股的估值“已满”。</li></blockquote></p><p></li>  <li><b>William Blair</b>&nbsp;analyst Kamil Mielczarek says Palantir revenues decelerated in the quarter to 36% year-over-year, down from 49% in the first half of 2021.</p><p><blockquote><li><b>威廉·布莱尔</b>分析师Kamil Mielczarek表示，Palantir本季度收入同比增速放缓至36%，低于2021年上半年的49%。</li></blockquote></p><p></li>  <li>While Palantir delivered \"strong\" headline numbers, the growth in the second half of 2021 is \"heavily reliant on strategic investments.\"</p><p><blockquote><li>尽管Palantir取得了“强劲”的总体数据，但2021年下半年的增长“严重依赖于战略投资”。</li></blockquote></p><p></li>  <li>The analyst remains concerned about the business's ability to maintain 30% organic growth over the near term and keeps an Underperform rating on Palantir.</p><p><blockquote><li>该分析师仍然担心该业务在短期内保持30%有机增长的能力，并维持对Palantir的跑输评级。</li></blockquote></p><p></li>  <li><b>Citi</b>&nbsp;analyst Tyler Radke states Palantir's decelerating growth \"came into center view\" in Q3 with weakness in both commercial and government.</p><p><blockquote><li><b>花旗银行</b>分析师泰勒·拉德克(Tyler Radke)表示，由于商业和政府的疲软，Palantir增长放缓在第三季度“成为人们关注的焦点”。</li></blockquote></p><p></li>  <li>While guidance for Q4 was issued slightly ahead of the Street, it still implies slower growth, even on an easier comparison and with significant tailwinds from SPAC-related customer contracting.</p><p><blockquote><li>尽管第四季度指引的发布略早于华尔街，但这仍然意味着增长放缓，即使进行更容易的比较，并且有SPAC相关客户合同的显着推动。</li></blockquote></p><p></li>  <li>He reiterates a Sell rating on the shares with an $18 price target.</p><p><blockquote><li>他重申对该股的卖出评级，目标价为18美元。</li></blockquote></p><p></li>  <li><b>Wolfe Research</b>&nbsp;analyst Alex Zukin lowered the price target to $20 from $25, and maintained a Peer Perform following what he calls an \"interesting\" Q3 report.</p><p><blockquote><li><b>沃尔夫研究</b>分析师Alex Zukin将目标价从25美元下调至20美元，并在评级“有趣”的第三季度报告后维持同行表现。</li></blockquote></p><p></li>  <li>He notes that shares were down after the announcement, which he blames a \"meaningful top-line deceleration,\" pointing out that total revenues, ex. SPAC-contributions of $373 million grew 29% year-over-year, which Zukin said is up only less than $1 million sequentially from Q2.</p><p><blockquote><li>他指出，公告发布后股价下跌，他将其归咎于“有意义的营收减速”，并指出总收入（例如。SPAC——3.73亿美元的捐款同比增长29%，Zukin表示，这一数字比第二季度仅增长了不到100万美元。</li></blockquote></p><p></li>  <li>His lower price target is due to the core growth deceleration as he is \"not yet comfortable assigning a similar confidence interval and multiple to SPAC-based commercial revenue.\"</p><p><blockquote><li>他较低的价格目标是由于核心增长减速，因为他“还不愿意为基于SPAC的商业收入分配类似的置信区间和倍数”。</li></blockquote></p><p></li>  <li><b>Morgan Stanley</b>&nbsp;analyst Keith Weiss raised the price target to $24 from $22, implying a 4% upside.</p><p><blockquote><li><b>摩根士丹利</b>分析师Keith Weiss将目标价从22美元上调至24美元，意味着上涨4%。</li></blockquote></p><p></li>  <li>He reiterated an Underweight after delivering another beat versus consensus expectations \"across all key headline metrics\" in Q3.</p><p><blockquote><li>在第三季度“所有关键总体指标”再次超出普遍预期后，他重申了跑输大盘。</li></blockquote></p><p></li>  <li>Weiss sees \"signs of slowing underneath the hood\" as a slowdown in core revenue and commercial growth, coupled with a sharper slowdown in the government segment, which opens up the debate on the durability of Palantir's growth.</p><p><blockquote><li>韦斯认为，“幕后放缓的迹象”是核心收入和商业增长放缓，加上政府部门的放缓幅度更大，这引发了关于Palantir增长持久性的争论。</li></blockquote></p><p></li>  <li><b>Price Action:</b>PLTR shares traded lower by 5.6% at $22.9 on the last check Wednesday.</p><p><blockquote><li><b>价格走势：</b>周三最后一次检查时，PLTR股价下跌5.6%，至22.9美元。</li></blockquote></p><p></li> </ul></p><p><blockquote></blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Analysts Adjust Palantir Price Targets Post Q3 Results<blockquote>分析师在第三季度业绩公布后调整Palantir价格目标</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnalysts Adjust Palantir Price Targets Post Q3 Results<blockquote>分析师在第三季度业绩公布后调整Palantir价格目标</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-11-11 16:26</span>\n</p>\n</h4>\n</header>\n<article>\n<p> <ul>  <li>Few analysts slashed price targets on<b>Palantir Technologies Inc</b>(NYSE:PLTR)despite the Q3 beat.</p><p><blockquote><ul><li>很少有分析师大幅下调目标价<b>Palantir技术公司</b>（纽约证券交易所股票代码：PLTR）尽管第三季度表现良好。</li></ul></blockquote></p><p></li>  <li><b>RBC Capital</b>analyst Rishi Jaluria downgraded toUnderperform from Sector Performwith a price target of $19, down from $25, implying a 17% downside.</p><p><blockquote><li><b>加拿大皇家银行资本</b>分析师Rishi Jaluria将行业表现评级从行业表现下调至表现不佳，目标价从25美元降至19美元，意味着下跌17%。</li></blockquote></p><p></li>  <li>The analyst cites the company's \"mixed\" Q3 results with deceleration in the government business while noting that its commercial acceleration that is being fueled by SPAC investments is \"unsustainable.\"</p><p><blockquote><li>该分析师指出，该公司第三季度业绩“好坏参半”，政府业务放缓，同时指出，SPAC投资推动的商业加速是“不可持续的”。</li></blockquote></p><p></li>  <li>Jaluria adds that his confidence in Palantr's 30% growth is reduced, and he sees the stock's valuation as \"full.\"</p><p><blockquote><li>Jaluria补充说，他对Palantr 30%增长的信心降低，他认为该股的估值“已满”。</li></blockquote></p><p></li>  <li><b>William Blair</b>&nbsp;analyst Kamil Mielczarek says Palantir revenues decelerated in the quarter to 36% year-over-year, down from 49% in the first half of 2021.</p><p><blockquote><li><b>威廉·布莱尔</b>分析师Kamil Mielczarek表示，Palantir本季度收入同比增速放缓至36%，低于2021年上半年的49%。</li></blockquote></p><p></li>  <li>While Palantir delivered \"strong\" headline numbers, the growth in the second half of 2021 is \"heavily reliant on strategic investments.\"</p><p><blockquote><li>尽管Palantir取得了“强劲”的总体数据，但2021年下半年的增长“严重依赖于战略投资”。</li></blockquote></p><p></li>  <li>The analyst remains concerned about the business's ability to maintain 30% organic growth over the near term and keeps an Underperform rating on Palantir.</p><p><blockquote><li>该分析师仍然担心该业务在短期内保持30%有机增长的能力，并维持对Palantir的跑输评级。</li></blockquote></p><p></li>  <li><b>Citi</b>&nbsp;analyst Tyler Radke states Palantir's decelerating growth \"came into center view\" in Q3 with weakness in both commercial and government.</p><p><blockquote><li><b>花旗银行</b>分析师泰勒·拉德克(Tyler Radke)表示，由于商业和政府的疲软，Palantir增长放缓在第三季度“成为人们关注的焦点”。</li></blockquote></p><p></li>  <li>While guidance for Q4 was issued slightly ahead of the Street, it still implies slower growth, even on an easier comparison and with significant tailwinds from SPAC-related customer contracting.</p><p><blockquote><li>尽管第四季度指引的发布略早于华尔街，但这仍然意味着增长放缓，即使进行更容易的比较，并且有SPAC相关客户合同的显着推动。</li></blockquote></p><p></li>  <li>He reiterates a Sell rating on the shares with an $18 price target.</p><p><blockquote><li>他重申对该股的卖出评级，目标价为18美元。</li></blockquote></p><p></li>  <li><b>Wolfe Research</b>&nbsp;analyst Alex Zukin lowered the price target to $20 from $25, and maintained a Peer Perform following what he calls an \"interesting\" Q3 report.</p><p><blockquote><li><b>沃尔夫研究</b>分析师Alex Zukin将目标价从25美元下调至20美元，并在评级“有趣”的第三季度报告后维持同行表现。</li></blockquote></p><p></li>  <li>He notes that shares were down after the announcement, which he blames a \"meaningful top-line deceleration,\" pointing out that total revenues, ex. SPAC-contributions of $373 million grew 29% year-over-year, which Zukin said is up only less than $1 million sequentially from Q2.</p><p><blockquote><li>他指出，公告发布后股价下跌，他将其归咎于“有意义的营收减速”，并指出总收入（例如。SPAC——3.73亿美元的捐款同比增长29%，Zukin表示，这一数字比第二季度仅增长了不到100万美元。</li></blockquote></p><p></li>  <li>His lower price target is due to the core growth deceleration as he is \"not yet comfortable assigning a similar confidence interval and multiple to SPAC-based commercial revenue.\"</p><p><blockquote><li>他较低的价格目标是由于核心增长减速，因为他“还不愿意为基于SPAC的商业收入分配类似的置信区间和倍数”。</li></blockquote></p><p></li>  <li><b>Morgan Stanley</b>&nbsp;analyst Keith Weiss raised the price target to $24 from $22, implying a 4% upside.</p><p><blockquote><li><b>摩根士丹利</b>分析师Keith Weiss将目标价从22美元上调至24美元，意味着上涨4%。</li></blockquote></p><p></li>  <li>He reiterated an Underweight after delivering another beat versus consensus expectations \"across all key headline metrics\" in Q3.</p><p><blockquote><li>在第三季度“所有关键总体指标”再次超出普遍预期后，他重申了跑输大盘。</li></blockquote></p><p></li>  <li>Weiss sees \"signs of slowing underneath the hood\" as a slowdown in core revenue and commercial growth, coupled with a sharper slowdown in the government segment, which opens up the debate on the durability of Palantir's growth.</p><p><blockquote><li>韦斯认为，“幕后放缓的迹象”是核心收入和商业增长放缓，加上政府部门的放缓幅度更大，这引发了关于Palantir增长持久性的争论。</li></blockquote></p><p></li>  <li><b>Price Action:</b>PLTR shares traded lower by 5.6% at $22.9 on the last check Wednesday.</p><p><blockquote><li><b>价格走势：</b>周三最后一次检查时，PLTR股价下跌5.6%，至22.9美元。</li></blockquote></p><p></li> </ul></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/analysts-adjust-palantir-price-targets-183049561.html\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://finance.yahoo.com/news/analysts-adjust-palantir-price-targets-183049561.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139881214","content_text":"Few analysts slashed price targets onPalantir Technologies Inc(NYSE:PLTR)despite the Q3 beat.\nRBC Capitalanalyst Rishi Jaluria downgraded toUnderperform from Sector Performwith a price target of $19, down from $25, implying a 17% downside.\nThe analyst cites the company's \"mixed\" Q3 results with deceleration in the government business while noting that its commercial acceleration that is being fueled by SPAC investments is \"unsustainable.\"\nJaluria adds that his confidence in Palantr's 30% growth is reduced, and he sees the stock's valuation as \"full.\"\nWilliam Blair analyst Kamil Mielczarek says Palantir revenues decelerated in the quarter to 36% year-over-year, down from 49% in the first half of 2021.\nWhile Palantir delivered \"strong\" headline numbers, the growth in the second half of 2021 is \"heavily reliant on strategic investments.\"\nThe analyst remains concerned about the business's ability to maintain 30% organic growth over the near term and keeps an Underperform rating on Palantir.\nCiti analyst Tyler Radke states Palantir's decelerating growth \"came into center view\" in Q3 with weakness in both commercial and government.\nWhile guidance for Q4 was issued slightly ahead of the Street, it still implies slower growth, even on an easier comparison and with significant tailwinds from SPAC-related customer contracting.\nHe reiterates a Sell rating on the shares with an $18 price target.\nWolfe Research analyst Alex Zukin lowered the price target to $20 from $25, and maintained a Peer Perform following what he calls an \"interesting\" Q3 report.\nHe notes that shares were down after the announcement, which he blames a \"meaningful top-line deceleration,\" pointing out that total revenues, ex. SPAC-contributions of $373 million grew 29% year-over-year, which Zukin said is up only less than $1 million sequentially from Q2.\nHis lower price target is due to the core growth deceleration as he is \"not yet comfortable assigning a similar confidence interval and multiple to SPAC-based commercial revenue.\"\nMorgan Stanley analyst Keith Weiss raised the price target to $24 from $22, implying a 4% upside.\nHe reiterated an Underweight after delivering another beat versus consensus expectations \"across all key headline metrics\" in Q3.\nWeiss sees \"signs of slowing underneath the hood\" as a slowdown in core revenue and commercial growth, coupled with a sharper slowdown in the government segment, which opens up the debate on the durability of Palantir's growth.\nPrice Action:PLTR shares traded lower by 5.6% at $22.9 on the last check Wednesday.","news_type":1,"symbols_score_info":{"PLTR":0.9}},"isVote":1,"tweetType":1,"viewCount":2510,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847242787,"gmtCreate":1636529421946,"gmtModify":1636529422091,"author":{"id":"3579647754039667","authorId":"3579647754039667","name":"HoSei","avatar":"https://static.tigerbbs.com/b65f0852010eb87e540514cf7506961d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579647754039667","authorIdStr":"3579647754039667"},"themes":[],"title":"","htmlText":"$24 range is a&nbsp;Great buy","listText":"$24 range is a&nbsp;Great buy","text":"$24 range is a Great buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847242787","repostId":"1105674649","repostType":2,"isVote":1,"tweetType":1,"viewCount":3030,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844412695,"gmtCreate":1636451155235,"gmtModify":1636455795644,"author":{"id":"3579647754039667","authorId":"3579647754039667","name":"HoSei","avatar":"https://static.tigerbbs.com/b65f0852010eb87e540514cf7506961d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579647754039667","authorIdStr":"3579647754039667"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Pay day!","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Pay day!","text":"$Palantir Technologies Inc.(PLTR)$Pay day!","images":[{"img":"https://static.tigerbbs.com/39f5d602b05e634df1b378548a609fb0","width":"750","height":"2567"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844412695","isVote":1,"tweetType":1,"viewCount":3435,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844341062,"gmtCreate":1636396890468,"gmtModify":1636396890638,"author":{"id":"3579647754039667","authorId":"3579647754039667","name":"HoSei","avatar":"https://static.tigerbbs.com/b65f0852010eb87e540514cf7506961d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579647754039667","authorIdStr":"3579647754039667"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>Share share","listText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>Share share","text":"$Pinterest, Inc.(PINS)$Share share","images":[{"img":"https://static.tigerbbs.com/9c182b95564d66208c97e2677672c2fc","width":"750","height":"2557"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844341062","isVote":1,"tweetType":1,"viewCount":3016,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842281805,"gmtCreate":1636181663868,"gmtModify":1636181664021,"author":{"id":"3579647754039667","authorId":"3579647754039667","name":"HoSei","avatar":"https://static.tigerbbs.com/b65f0852010eb87e540514cf7506961d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579647754039667","authorIdStr":"3579647754039667"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>Share&nbsp;","listText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>Share&nbsp;","text":"$Pinterest, Inc.(PINS)$Share","images":[{"img":"https://static.tigerbbs.com/0814ceec8bf114ea928080df8fe5a29a","width":"750","height":"2747"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842281805","isVote":1,"tweetType":1,"viewCount":2662,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846793967,"gmtCreate":1636111442688,"gmtModify":1636111442785,"author":{"id":"3579647754039667","authorId":"3579647754039667","name":"HoSei","avatar":"https://static.tigerbbs.com/b65f0852010eb87e540514cf7506961d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579647754039667","authorIdStr":"3579647754039667"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Share","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Share","text":"$Palantir Technologies Inc.(PLTR)$Share","images":[{"img":"https://static.tigerbbs.com/df82625bccca4b69cc0d7b8db8e2e937","width":"750","height":"2747"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846793967","isVote":1,"tweetType":1,"viewCount":2861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846790678,"gmtCreate":1636111208772,"gmtModify":1636111208918,"author":{"id":"3579647754039667","authorId":"3579647754039667","name":"HoSei","avatar":"https://static.tigerbbs.com/b65f0852010eb87e540514cf7506961d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579647754039667","authorIdStr":"3579647754039667"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>Too good to miss","listText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>Too good to miss","text":"$Pinterest, Inc.(PINS)$Too good to miss","images":[{"img":"https://static.tigerbbs.com/103cc76613c65f459e05d5c41be26f9c","width":"750","height":"1464"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846790678","isVote":1,"tweetType":1,"viewCount":3041,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848811455,"gmtCreate":1635988498720,"gmtModify":1635988498831,"author":{"id":"3579647754039667","authorId":"3579647754039667","name":"HoSei","avatar":"https://static.tigerbbs.com/b65f0852010eb87e540514cf7506961d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579647754039667","authorIdStr":"3579647754039667"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>To the moon tonight&nbsp;","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>To the moon tonight&nbsp;","text":"$Palantir Technologies Inc.(PLTR)$To the moon tonight","images":[{"img":"https://static.tigerbbs.com/f3428097887558839f6c9a8958c06aae","width":"750","height":"1464"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848811455","isVote":1,"tweetType":1,"viewCount":2573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}